Lilly and Incyte highlight positive data for Olumiant in rheumatoid arthritis

The FINANCIAL — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today positive data for Olumiant® (baricitinib) will be presented at ACR Convergence 2020, the American College of Rheumatology’s virtual annual meeting taking place November 5-9, 2020. The Olumiant data being presented at this year’s meeting…

15 mins read

Lilly to acquire Disarm Therapeutics

THe FINANCIAL — Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire Disarm Therapeutics, a privately-held biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration. Disarm has discovered novel, potent SARM1 inhibitors and is advancing…

3 mins read